Bibliographic Details
| Title: |
Avapritinib versus Placebo in Indolent Systemic Mastocytosis. |
| Authors: |
Gotlib, Jason, Castells, Mariana, Elberink, Hanneke Oude, Siebenhaar, Frank, Hartmann, Karin, Broesby-Olsen, Sigurd, George, Tracy I., Panse, Jens, Alvarez-Twose, Iván, Radia, Deepti H., Tashi, Tsewang, Bulai Livideanu, Cristina, Sabato, Vito, Heaney, Mark, Van Daele, Paul, Cerquozzi, Sonia, Dybedal, Ingunn, Reiter, Andreas, Pongdee, Thanai, Barete, Stéphane |
| Source: |
NEJM Evidence; Jun2023, Vol. 2 Issue 6, p1-15, 15p |
| Subject Terms: |
THERAPEUTIC use of antineoplastic agents, DRUG efficacy, ALKALINE phosphatase, CONFIDENCE intervals, MAST cell disease, HEALTH outcome assessment, ALLELES, PLACEBOS, RANDOMIZED controlled trials, HYDROLASES, COMPARATIVE studies, DESCRIPTIVE statistics, MAST cells, QUALITY of life, STATISTICAL sampling, BONE marrow, PATIENT safety |
| Abstract: |
Background: Indolent systemic mastocytosis (ISM) is a clonal mast-cell disease driven by the KIT D816V mutation. We assessed the efficacy and safety of avapritinib versus placebo, both with best supportive care, in patients with ISM. Methods: We randomized patients with moderate to severe ISM (total symptom score [TSS] of ≥28; scores range from 0 to 110, with higher numbers indicating more severe symptoms) two to one to avapritinib 25 mg once daily (n=141) or placebo (n=71). The primary end point was mean change in TSS based on the 14-day average of patient-reported severity of 11 symptoms. Secondary end points included reductions in serum tryptase and blood KIT D816V variant allele fraction (≥50%), reductions in TSS (≥50% and ≥30%), reduction in bone marrow mast cells (≥50%), and quality of life measures. Results: From baseline to week 24, avapritinib-treated patients had a decrease of 15.6 points (95% CI, -18.6 to -12.6) in TSS compared to a decrease of 9.2 points (-13.1 to -5.2) in the placebo group; P<0.003. From baseline to Week 24, 76/141 patients (54%; 45% to 62%) in the avapritinib group compared to 0/71 patients in the placebo group achieved a ≥50% reduction in serum tryptase level; P<0.001. Edema and increases in alkaline phosphatase were more common with avapritinib than placebo; there were few treatment discontinuations because of adverse events. Conclusions: In this trial, avapritinib was superior to placebo in reducing uncontrolled symptoms and mast-cell burden in patients with ISM. The long-term safety and efficacy of this approach for patients with ISM remain the focus of the ongoing trial. (Funded by Blueprint Medicines Corporation; ClinicalTrials.gov number, NCT03731260.) [ABSTRACT FROM AUTHOR] |
|
Copyright of NEJM Evidence is the property of MMS Publications and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Supplemental Index |
